scPharmaceuticals Inc

-0.11 (-2.05%)
Earnings Announcements

Scpharmaceuticals Inc. Announces Positive Top-Line Results From Freedom-Hf Study

Published: 07/13/2021 20:23 GMT
scPharmaceuticals Inc (SCPH) - Scpharmaceuticals Inc. Announces Positive Top-line Results From Freedom-hf Study.
Scpharmaceuticals - Study Halted Early Due to Highly Statistically Significant Reduction in 30-day Heart Failure-related Costs in Prespecified Interim Analysis.
Scpharmaceuticals - Reduced Average 30-day Heart Failure Related Costs by $17,753 per Study Subject in Furoscix Versus Historically Matched Comparators.
Scpharmaceuticals Inc - No Serious Adverse Events Related to Furoscix Were Observed.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.